Abnormalities in lipid metabolism, associated with increased risk of cardiovascular disease (CVD), frequently occur in people with diabetes. Eryngium carlinae is a plant used in traditional medicine to treat lipid abnormalities. The chemical composition and hypolipidemic activity of the ethanolic extract of E. carlinae were analyzed to broaden our knowledge of its mechanism of action. The ethanolic extract of E. carlinae was tested for hypolipidemic activity by oral administration for 40 days. Atorvastatin, a widely used statin, was also administered to compare its effect with that of the extract. Serum was used for analysis of the lipid profile and liver microsomes to assess 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity and low-density lipoprotein receptor (LDL-r) levels. The extract was able to reduce total cholesterol and non-high-density lipoprotein cholesterol (C-HDL) levels and increase the C-HDL levels reduced in diabetes, decreasing the atherogenic index and therefore the risk of suffering CVD at the same level as atorvastatin. The HMG-CoA reductase activity and LDL-r levels were not modified by the administration of E. carlinae. The results demonstrate the hypolipidemic potential of ethanol extract of E. carlinae and support its use in traditional medicine as a hypolipidemic agent.
Get full access to this article
View all access options for this article.
References
1.
American Diabetes Association (ADA): Diagnosis and classification of diabetes mellitus. Diabetes Care, 2004; 27(suppl 1):S5–S10.
2.
International Diabetes Federation (IDF): Diabetes and Cardiovascular Disease. International Diabetes Federation, Brussels, Belgium, 2016; https://www.idf.org/our-activities/care-prevention/cardiovascular-disease.html#introarea (accessed July5, 2019).
3.
DivyaBT, MiniS: Ethanol extract of Butea monosperma bark modulates dyslipidemia in streptozotocin-induced diabetic rats. Pharm Biol, 2014; 52:1021–1027.
4.
KraussRM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care, 2004; 27:1496–1504.
5.
SenaCM, MatafomeP, LouroT, et al.: Effects of atorvastatin and insulin in vascular dysfunction associated with type 2 diabetes. Physiol Res, 2014; 63:189–197.
6.
FrancoD, HenaoY, MonsalveM, et al.: Hypolipidemic agents drug interactions: Approach to establish and assess its clinical significance. Structured review. Farm Hosp, 2013; 37:539–557.
7.
Jamshidi-KiaF, LorigooiniZ, Amini-KhoeiH: Medicinal plants: Past history and future perspective. J Herbmed Pharmacol, 2018; 7:1–7.
8.
GovernaP, BainiG, BorgonettiV, et al.: Phytotherapy in the management of diabetes: A review. Molecules, 2018; 23:105.
9.
García-CerrilloD, Noriega-CisnerosR, Peña-MontesD, et al.: Antioxidant effects of Eryngium carlinae in diabetic rats. Asian J Appl Sci, 2018; 6:308–314.
10.
Peña-MontesDJ, Huerta-CervantesM, Ríos-SilvaM, et al.: Protective effect of the hexanic extract of Eryngium carlinae inflorescences in vitro, in yeast, and in streptozotocin-induced diabetic male rats. Antioxidants, 2019; 8:pii: E73.
11.
Castro-TorresIG, De la O-ArciniegaM, Naranjo-RodríguezEB, et al.: The hypocholesterolemic effects of Eryngium carlinae F. Delaroche are mediated by the involvement of the intestinal transporters ABCG5 and ABCG8. Evid Based Complement Alternat Med, 2017; 2017:3176232.
12.
Noriega-CisnerosR, Ortiz-ÁvilaO, Esquivel-GutiérrezE, et al.: Hypolipidemic activity of Eryngium carlinae on streptozotocin-induced diabetic rats. Biochem Res Int, 2012; 2012:603501.
13.
MillánJ, PintóX, MuñozA, et al.: Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag, 2009; 5:757–765.
14.
AdamsRP: Identification of Essential Oil Components by Gas Chromatography/Mass Spectrometry. 4th ed. Allured Publishing Corporation, Carol Stream, IL, USA,, 2007; 31–52.
15.
RanjitP, GuntukuG, PothineniR: New atherogenic indices: Assessment of cardio vascular risk in post menopausal dyslipidemia. Asian J Med Sci, 2015:6:25–32.
16.
WägnerAM, PérezA, ZapicoE, et al.: Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care, 2003; 26:2048–2051.
17.
HondaA, SalenG, MatsuzakiY, et al.: Differences in hepatic levels of intermediates in bile acid biosynthesis between Cyp27(-/-) mice and CTX. J Lipid Res, 2001; 42:291–300.
18.
LowryOH, RosebroughNJ, FarrAL, et al.: Protein measurement with the Folin phenol reagent. J Biol Chem, 1951; 193:265–275.
19.
EdwardsPA, LemongelloD, FogelmanAM: Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Lipid Res, 1979; 20:40–46.
20.
YangRL, ShiYH, HaoG, et al.: Increasing oxidative stress with progressive hyperlipidemia in human: Relation between malondialdehyde and atherogenic index. J Clin Biochem Nutr, 2008; 43:154–158.
21.
FunatsuT, SuzukiK, GotoM, et al.: Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis, 2001; 157:107–115.
22.
FernandesES, PassosGF, MedeirosR, et al.: Anti-inflammatory effects of compounds alpha-humulene and (-)-trans-caryophyllene isolated from the essential oil of Cordia verbenacea. Eur J Pharmacol, 2007; 569:228–236.
23.
ZhanYH, LiuJ, QuXJ, et al.: β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/mTOR signalling pathways. Asian Pac J Cancer Prev, 2012; 13:2739–2744.
24.
ChungIM, KimMY, ParkWH, et al.: Antiatherogenic activity of Dendropanax morbifera essential oil in rats. Pharmazie, 2009; 64:547–549.
25.
Kumar TyagiA, BukvickiD, GottardiD, et al.: Antimicrobial potential and chemical characterization of Serbian Liverwort (Porella arboris-vitae): SEM and TEM observations. Evid Based Complement Alternat Med, 2013; 2013:382927.
26.
Ben HsounaA, HamdiN: Phytochemical composition and antimicrobial activities of the essential oils and organic extracts from Pelargonium graveolens growing in Tunisia. Lipids Health Dis, 2012; 11:167.
27.
CárdenasJ, RojasJ, Rojas-FerminL, et al.: Essential oil composition and antibacterial activity of Monticalia greenmaniana (Asteraceae). Nat Prod Commun, 2012; 7:243–244.
28.
HegstedDM, McGandyRB, MyersML, et al.: Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr, 1965; 17:281–295.
29.
BattaAK, XuG, HondaA, et al.: Stigmasterol reduces plasma cholesterol levels and inhibits hepatic synthesis and intestinal absorption in the rat. Metabolism, 2006; 55:292–299.
30.
SiddiqA, KhanRA, BaigSG: Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?. J Pharm Bioallied Sci, 2011; 3:306–309.
31.
PareekA, YeolePG, TenpeCR, et al.: Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats. Indian J Pharmacol, 2009; 41:125–128.
32.
WalldiusG, JungnerI, HolmeI, et al.: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet, 2001; 358:2026–2033.
33.
CuiY, BlumenthalRS, FlawsJA, et al.: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med, 2001; 161:1413–1419.
34.
AngelinB, EinarssonK, LiljeqvistL, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase in human liver microsomes: Active and inactive forms and cross-reactivity with antibody against rat liver enzyme. J Lipid Res, 1984; 25:1159–1166.
35.
NessGC, ZhaoZ, LopezD: Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys, 1996; 325:242–248.
